2Caixia T, Hongwen F, Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci, 1999,21 (1):59.
3Yu HS, Chang KL, Yu CL, et al. Alterations in IL-6,IL-8, GM- CSF, TNF-alpha and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol , 1997, 108(4): 527.
4Swope VB, Malek ZA, Kassem LM, et al. Interleukins 1 a and 6 and tumor necrosis factor a are paracrine inhibitors of human melanocyte proliferation and mela nogeneis. J Invest Dermatol, 1991,96(2): 180.
5Kimbauer R, Charvat B, Schauter K, et al. Modulation of intercelluar adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for aregulatory role of IL-5, IL-7,TNF-a and UVB light.J Invest Dermatol, 1992,98(3): 320.
6Bernstein D, Reddy KR, Jeffers L, et al. Canities and vitiligo complicating interferon therapy for hepatitis C.Am J Gastroenterol, 1995,90(7): 1176.
7Hwang JH, Ahn JS, Kim SD, et al. The changes of serum soluble intercellular adhesion molecule-1 after steroid treatment in vitiligo. J Dermatol Sci, 1999, 22(1): 11.
8Mozzanica N, Villa ML, Foppa S, et al. Plasma alphamelanocyte-stimulating hormone, beta-endorphin and natural killer cell activity in vitiligo. J Am Acad Dermatol, 1992, 26(5 pt 1): 693.
9Al'Abadie MS,Senior HJ, Bleehen SS, et al. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol, 1994,131 (2):160.
10Liu PY, Bondesson IL, Lontz W, et al. The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris. Arch Dermatol Res, 1996,288(11) : 670.
